Low-Dose radiation plus immunotherapy shows promise in rectal cancer trial
NCT ID NCT07448142
First seen Apr 18, 2026 · Last updated Jun 18, 2026 · Updated 7 times
Summary
This study tests a new approach for people with a common type of locally advanced rectal cancer. It combines low-dose radiation with an immunotherapy drug (pucotenlimab) and chemotherapy before surgery. The goal is to see if this combination can make the tumor disappear completely, either before or after surgery. About 50 adults will take part, and the study will also track long-term outcomes like cancer recurrence and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651
RECRUITINGGuangzhou, Guanggong, 510060, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.